The best HRT for hair loss is a common concern for women navigating perimenopause and menopause, when declining oestrogen levels can trigger or worsen hair thinning. Choosing the right hormonal regimen involves understanding how different oestrogen formulations and progestogens interact with hair follicles, as well as recognising that HRT is not licensed in the UK specifically for hair loss. This guide explains the hormonal mechanisms behind menopausal hair thinning, which HRT types are most relevant, what the evidence actually shows, and how to have an informed conversation with your GP or menopause specialist about your options.

How Hormonal Changes Cause Hair Loss in Women

Declining oestrogen at perimenopause shortens the hair growth (anagen) phase, increasing shedding; relative androgen excess can also drive female-pattern hair loss, though genetic factors and other causes must be excluded.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss in women is frequently linked to hormonal fluctuations, particularly those occurring during perimenopause and menopause. As oestrogen and progesterone levels decline, the relative influence of androgens — male hormones present in small amounts in all women — becomes more pronounced. This hormonal shift can contribute to androgenetic alopecia (female-pattern hair loss), characterised by diffuse thinning across the crown and top of the scalp.

It is important to note that female-pattern hair loss frequently has a genetic basis and may coincide with, but is not solely caused by, menopause. Oestrogen plays a role in the hair growth cycle by helping to prolong the anagen (growth) phase of hair follicles. When oestrogen levels fall, follicles may spend more time in the telogen (resting) phase, leading to increased shedding and reduced regrowth. This process is gradual and may begin several years before the final menstrual period.

Not all hair loss in menopausal women is hormone-related. A GP assessment is essential before attributing hair thinning solely to menopause. Investigations should be selective and guided by clinical history and examination, rather than routine. Depending on your symptoms, a GP may consider:

• Full blood count (to check for anaemia)

• Serum ferritin (iron stores)

• Thyroid function tests (TSH)

• Assessment for signs of hyperandrogenism (e.g., hirsutism, acne, or menstrual irregularity), which may prompt measurement of total testosterone and SHBG, or referral

Vitamin D, B12, and zinc testing should be reserved for cases where there is a clinical indication, rather than performed routinely. In women aged over 45, NICE guideline NG23 advises against routine measurement of FSH, LH, or oestradiol to diagnose menopause, and these are not standard first-line tests for hair loss. Guidance from NICE CKS and the Primary Care Dermatology Society (PCDS) on female-pattern hair loss provides a useful framework for investigation and referral in primary care.

Other contributing factors to consider include:

• Thyroid dysfunction (both hypothyroidism and hyperthyroidism)

• Iron deficiency anaemia

• Chronic stress or significant life events

• Autoimmune conditions such as alopecia areata

Understanding the root cause of hair loss is critical to selecting the most appropriate treatment pathway.

Which Types of HRT May Help With Hair Thinning

Systemic oestrogen is the HRT component most relevant to hair health; combined regimens using progestogens with neutral or anti-androgenic profiles — such as micronised progesterone or dydrogesterone — are generally preferred over androgenic progestogens.

Hormone replacement therapy (HRT) works by replenishing declining levels of oestrogen and, where appropriate, progesterone. By restoring a more balanced hormonal environment, HRT may help slow the hair thinning associated with menopause in some women. However, HRT does not have a UK licence for the treatment of hair loss, and any benefit to hair is considered a secondary and variable effect. Individual responses differ considerably.

Oestrogen-based HRT is the component most relevant to hair health. By raising circulating oestrogen levels, it may help re-extend the anagen phase of the hair cycle, potentially reducing excessive shedding. Systemic oestrogen — delivered via patches, gels, sprays, or tablets — is the relevant form here. Local (vaginal) oestrogen preparations are intended to treat genitourinary symptoms and are not expected to have a meaningful effect on scalp hair.

The type of progestogen included in combined HRT is a clinically relevant consideration, though it is important to note that the evidence for progestogen-specific effects on hair is largely based on receptor profiles and limited observational data, rather than robust clinical trials. Some synthetic progestogens with androgenic properties — such as norethisterone and levonorgestrel — may theoretically counteract the beneficial effects of oestrogen on hair. Progestogens with anti-androgenic or neutral profiles are generally considered more favourable in this context. These include:

• Dydrogesterone (found in Femoston)

• Micronised progesterone (Utrogestan), which is body-identical and has a neutral androgenic profile

• Drospirenone (found in Angeliq), which has mild anti-androgenic activity

The primary purpose of the progestogen component in combined HRT is endometrial protection, and this must remain the priority when selecting a regimen. Any preference for a particular progestogen on the basis of hair concerns should be discussed with a clinician in the context of your overall benefit–risk profile.

For women who have had a hysterectomy, oestrogen-only HRT removes the progestogen variable entirely. Discussing the full HRT regimen with a clinician — ideally one with menopause expertise — is the appropriate way to tailor treatment to individual needs.

HRT Formulations and Their Effects on Hair Growth

Transdermal oestrogen (patches, gels, sprays) is associated with a lower VTE risk than oral oestrogen; micronised progesterone (Utrogestan) has a neutral androgenic profile, though direct evidence linking any specific formulation to improved hair outcomes remains limited.

The route of administration and specific formulation of HRT may influence its tolerability and safety profile, though direct evidence linking route of delivery to improved hair outcomes is limited.

Transdermal oestrogen — delivered via patches or gels applied to the skin — bypasses first-pass liver metabolism and is associated with a lower risk of venous thromboembolism (VTE) compared to oral oestrogen. This is an important safety consideration when choosing a formulation. Transdermal options available in the UK include:

• Oestrogen patches (e.g., Evorel, Estradot)

• Oestrogen gels (e.g., Oestrogel, Sandrena)

• Oestrogen sprays (e.g., Lenzetto)

Oral oestrogen raises levels of sex hormone-binding globulin (SHBG) via hepatic effects, which alters the balance of free sex hormones in the circulation. The net impact of this on hair follicles is not well established, and claims about route-specific hair benefits should be interpreted cautiously in the absence of robust evidence.

Micronised progesterone (Utrogestan) is increasingly used in body-identical HRT regimens. Its licensed route of administration is oral; use vaginally for endometrial protection within an HRT regimen is off-label in the UK, and women should be made aware of this if it is recommended. Its neutral-to-favourable androgenic receptor profile makes it a commonly discussed option for women with hair concerns, though again, evidence specific to hair outcomes is limited.

Testosterone therapy is sometimes prescribed off-label for postmenopausal women with hypoactive sexual desire disorder (HSDD), in line with NICE NG23 and British Menopause Society (BMS) guidance. It is not indicated for fatigue or hair loss. Women considering testosterone should be aware that, if levels exceed the normal female physiological range, androgenic side effects — including acne, hirsutism, and worsening of scalp hair loss — can occur. Use should be initiated and monitored by a specialist, with regular measurement of serum testosterone to ensure levels remain within the female reference range. The MHRA does not licence any testosterone product specifically for women in the UK, and prescribing is on a shared-care or specialist basis.

Experiencing these side effects? Our pharmacists can help you navigate them →

What the Evidence Says About HRT and Hair Loss

Evidence for HRT as a hair loss treatment is limited; oestrogen receptors exist in hair follicles and some women report benefit, but controlled trial data on hair endpoints are lacking and HRT is not a licensed or first-line treatment for hair loss.

The evidence base specifically examining HRT as a treatment for female hair loss remains limited, and it is important to approach this topic with appropriate caution. Most research on HRT has focused on its effects on vasomotor symptoms, bone density, and cardiovascular risk, rather than hair outcomes. HRT does not have a licensed indication for hair loss in the UK and should not be started solely for this purpose.

That said, observational data and biological plausibility support a rationale for oestrogen's role in hair cycle regulation. Oestrogen receptors have been identified in hair follicles, and some women report improvements in hair shedding or density after starting HRT. However, these reports are not consistent across individuals, and controlled trial data specifically on hair endpoints are lacking. Any quoted timeframes for response (such as six to twelve months) are based on clinical experience and limited observational data rather than high-quality evidence.

The choice of progestogen has been discussed in dermatological literature as a potentially relevant variable, with androgenic progestogens theoretically less favourable for hair. This remains largely based on receptor-profile reasoning rather than direct clinical evidence of superiority for hair outcomes.

Women should be counselled that:

• HRT is not a licensed or first-line treatment for hair loss

• Any benefit to hair is a secondary and uncertain effect

• Results vary significantly between individuals

• Hair regrowth, if it occurs, is typically gradual

• HRT carries its own risk profile, which must be weighed against benefits in the context of all menopausal symptoms

• If no meaningful improvement in hair is observed after a reasonable trial period, this should be reviewed with a clinician

NICE guideline NG23 recommends that HRT decisions be individualised, taking into account a woman's full medical history, symptom burden, and personal preferences. Guidance from the PCDS and British Association of Dermatologists (BAD) provides the most relevant framework for managing female-pattern hair loss specifically.

Speaking to Your GP or Specialist About HRT Options

Raise hair thinning with your GP as part of a broader menopausal health review; selective investigations (ferritin, TSH, full blood count) should guide management, and referral to a BMS-accredited menopause specialist or dermatologist is appropriate if needed.

If you are experiencing hair thinning alongside other menopausal symptoms, it is worth raising this with your GP as part of a broader conversation about hormonal health. Hair loss can be a distressing symptom and deserves to be taken seriously within a clinical consultation. Be prepared to describe the pattern of hair loss, when it began, any associated symptoms (such as hirsutism, acne, or menstrual irregularity), and any relevant family history of hair thinning.

Your GP will guide investigations based on your clinical history and examination findings. Routine testing of FSH, LH, and oestradiol is not recommended in women aged over 45 for the diagnosis of menopause (NICE NG23), and these are not standard first-line tests for hair loss. Selective tests that may be considered include:

• Full blood count (to check for anaemia)

• Serum ferritin (iron stores)

• Thyroid function tests (TSH)

• Vitamin D or B12, only if clinically indicated

• Total testosterone and SHBG, if there are features of hyperandrogenism (e.g., hirsutism, acne, or irregular periods)

If HRT is being considered, it is entirely appropriate to ask about the progestogen component and its androgenic profile. Requesting a body-identical or anti-androgenic progestogen is a reasonable, evidence-informed preference to discuss. If your GP is uncertain, a referral to a menopause specialist — many of whom hold British Menopause Society (BMS) accreditation — or a dermatologist with an interest in hair disorders may be appropriate.

Seek prompt medical advice if you notice:

• Sudden or rapid hair loss

• Patchy hair loss (which may suggest alopecia areata)

• Hair loss accompanied by scalp inflammation, scaling, or scarring

• Signs of virilisation (e.g., deepening voice, significant hirsutism) or a markedly raised testosterone level

• Significant hair shedding shortly after starting or changing HRT

The latter may represent telogen effluvium triggered by hormonal change, which is usually temporary but warrants clinical review. Scarring alopecia, rapid progression with scalp inflammation, or features of virilisation require prompt specialist referral. Open communication with your healthcare team is essential to finding the most suitable and safe approach.

Other Treatments Used Alongside HRT for Hair Loss

Topical minoxidil (5% foam, once daily) is the only UK-licensed treatment for female-pattern hair loss and is often used alongside HRT; anti-androgens such as spironolactone may be considered off-label under specialist supervision.

For many women, HRT alone may not fully address hair thinning, and a combination approach is often most effective. Several evidence-based and clinically recognised treatments can be used alongside HRT to support hair regrowth and reduce further loss.

Topical minoxidil is the only treatment currently licensed in the UK specifically for female-pattern hair loss. The 5% minoxidil foam (e.g., Regaine for Women Once a Day 5% Cutaneous Foam) is licensed for use in women, applied once daily. The 5% solution is generally licensed for men; use in women would be off-label. The 2% solution is also licensed for women. Minoxidil works by prolonging the anagen phase and increasing blood flow to hair follicles. It must be used consistently, and results may take three to six months to become apparent. An initial increase in shedding can occur in the first few weeks and is usually temporary. NICE CKS and the British Association of Dermatologists (BAD) recognise minoxidil as a first-line option for androgenetic alopecia. Ongoing use is required to maintain benefit.

Anti-androgen medications may be considered in women with evidence of elevated androgens or significant androgenetic alopecia. Spironolactone, used off-label in the UK, blocks androgen receptors at the hair follicle and has shown benefit in some studies. It requires monitoring of renal function and serum potassium (U&Es), particularly in women with renal impairment or those taking interacting medicines. It is contraindicated in pregnancy, and effective contraception is essential for women of reproductive age. Finasteride, a 5-alpha reductase inhibitor, is occasionally used off-label in postmenopausal women under specialist supervision. It carries a significant teratogenic risk and is contraindicated in women who are pregnant or may become pregnant; it is not routinely recommended.

Additional supportive measures include:

• Nutritional optimisation: Correcting confirmed deficiencies in ferritin, vitamin D, or zinc where identified on testing. Routine biotin supplementation is not supported by evidence in the absence of confirmed deficiency, and high-dose biotin can interfere with certain laboratory assays — the MHRA has issued a safety update on this risk.

• Low-level laser therapy (LLLT): Some evidence supports its use as an adjunct, though it is not NHS-funded and evidence remains limited.

• Platelet-rich plasma (PRP) therapy: An emerging treatment available privately, with growing but not yet conclusive evidence.

• Gentle hair care practices: Avoiding excessive heat, tight hairstyles, and harsh chemical treatments.

If you experience a suspected side effect from any medicine used for hair loss or HRT, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

A multidisciplinary approach — involving a GP, menopause specialist, and dermatologist where needed — offers the best chance of meaningful improvement in hair health alongside effective management of menopausal symptoms.

Frequently Asked Questions